Anales de la RANM

60 A N A L E S R A N M R E V I S T A F U N D A D A E N 1 8 7 9 SERUM MYELOPEROXIDASE AND PARKINSON´S DISEASE Fernández-Espejo E An RANM. 2022;139(01): 56 - 66 Table 1.- Demographic and clinical parameters as well as MPO levels in serum and the cerebrospinal fluid in the patients with PD and controls Parameters PD (n=36) Controls (n=30) P Age, years 65.6±9 68.4±12 NS Gender, male n (%) 21 (58) 12 (40) NS Hypertension, n (%) 14 (39) 5 (16.6) <.001 Diabetes, n (%) 2 (5.5) 2 (6.6) NS Levodopa equivalent daily dose, mg 587.9±809 Disease duration, years 10.4±8.5 Age at PD onset, years 54.9±14 Hoehn and Yahr stage 2.1±0.8 Total MDS-UPDRS (I-III) (on) 40.9±23 MDS-UPDRS part III (on) 27.2±13 MDS-UPDRS part IV (all patients) 1.5±2 Biofluids content Serum MPO (pg/ml) 4,098±2,865 1,430±683 <.0001 CSF MPO (pg/ml) 109±69 98±44 NS Serum/CSF ratio of MPO 46±28 20±16 <.0001 Serum MPO versus CSF MPO (Pearson´s r) -.202 -.168 NS Hoehn Yahr stage and serum MPO content (pg/ml) PD Control Early disease (H-Y stage 1-2; n=25) 3,011±1,790 1,430±683 <.0001 Moderate-advanced disease (H-Y stage 3; n=11) 6,569±3372 ** 1,430±683 <.0001 Hoehn Yahr stage and CSF MPO content (pg/ml) Early disease 95±64 98±44 NS Moderate-advanced disease 142±72 98±44 NS Mean ± SD. Statistical comparisons were carried out with the χ2 test (dychotomous variables) or the Student’s t test (quanti- tative variables), and Bonferroni correction. ** P=.0002 vs. early disease. Abbrev.: CSF, cerebrospinal fluid; H-Y, Hoehn and Yahr; PD, Parkinson’s disease; MPO, myeloperoxidase; NS, no significant; MDS-UPDRS, International Parkinson and Mo- vement Disorder Society-Sponsored revision of the Unified Parkinson’s Disease Rating Scale; P, two-tailed probability value.